I love 60 minutes. I love recovery. I love Michael Botticelli(sober 27 years).
This is going to be one of Obama’s single most powerful decisions that will positively influence the whole country on so many levels. After being unanimously confirmed by the Senate(by a vote of 92-0), Michael Botticelli was sworn in as Director of National Drug Control Policy at the White House on February 11, 2015 and has been blasting down the doors of stigma ever since.
If you want to know anything about addiction and how it impacts your community and tax dollars, please watch this video!
OR CLICK HERE IF THE FIRST LINK DIDN’T WORK.
After achieving sobriety, Botticelli joined the Massachusetts Department of Public Health, in 1994. He worked as a coordinator for alcoholism programs from 1994 through 1995, as contract manager for HIV-related policies and services from 1995 through 1996, as an assistant director for policy and planning from 1996 through 2000, as the chief of staff to the public health commissioner from 2000 through 2003, and as director of substance abuse services from 2003 to 2012. In the latter role, he oversaw the pilot program for Quincy, Massachusetts, police to begin carrying naloxone to treat opioidoverdose, and the expansion of substance abuse treatment services in community health centers.
Gil Kerlikowske, serving as the director of the Office of National Drug Control Policy (ONDCP) under President Barack Obama, met Botticelli on a visit to Massachusetts and asked him to serve as deputy director. In March 2014, following Kerlikowske’s confirmation as commissioner of U.S. Customs and Border Protection, Botticelli became acting director. He is the first director of the ONDCP to be in recovery for substance use. The United States Senate confirmed Botticelli in February 2015 by a vote of 92-0. As director of ONDCP, Botticelli has advocated to expand the usage of naloxone, improved education for providers around prescription painkillers and providing clean syringes for injection drug users to limit the spread of HIV and Hepatitis C.